Epigenetics collaboration to boost understanding of Alzheimers

Clinical stage pharmaceutical company PharmaKure has announced a collaboration with Sheffield Hallam University to better understand the mechanisms of Alzheimer’s disease.

The collaboration will enhance the ability of researchers to identify those more at risk of developing brain diseases to enable earlier interventions.

This partnership will focus on ‘gene-based environmental biomarkers’, known as epigenetic markers, for calculating risk scores for Alzheimer’s diseases. Together with ALZmetrix, PharmaKure’s blood-based biomarker, the combined work will increase the power of current Alzheimer’s diagnostics.

The collaborative study between Sheffield Hallam University and Pharmakure aims to gain a better understanding of Alzheimer's Disease (AD) in order to identify those more at risk of developing the disease, so enabling the provision of appropriate interventions much earlier in the disease pathology. 

Professor Gavin Reynolds, Biomolecular Sciences Research Centre, Sheffield Hallam University, said: “We have been working on the relationship of environmental stresses with respect to brain diseases.” Professor Reynolds has published over 300 papers on the pathology of neurotransmitter systems involved in psychiatric disorders and now focuses on epigenetics effects in neuro diseases. “Our genes are coded in our DNA, but epigenetics looks at how the cell turns genes on and off according to different environmental exposure, such as the aging process, stress, trauma etc. We want to identify abnormal epigenetic changes associated with brain diseases, and these changes may be modifiable with medications.”

Dr Helene Fachim, Neuroscientist, PharmaKure, said, “Mental health and the environment can both contribute to the development of brain diseases. Influences, such as trauma and chronic stress, can bring about epigenetic changes to DNA that may result in a range of psychiatric and neurological disorders. We are therefore looking for epigenetic factors that are specifically related to Alzheimer’s Disease.”

“We would like to use these epigenetic approaches for a better understanding of AD, so that we can stratify a person’s risk of developing it. Then, we could act in preventive ways, or administer AD drugs earlier in life when they are more effective.”

Recent Issues